Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4310 |
Prexasertib
5-[[5-[2-(3-氨基丙氧基)-6-甲氧基苯基]-1H-吡唑-3-基]氨基]-2-吡嗪甲腈,LY2606368 |
Apoptosis; Chk | Apoptosis; Cell Cycle/Checkpoint |
Prexasertib (LY2606368) 是一种具有潜在抗肿瘤活性的检查点激酶 1 抑制剂。它可引起双链 DNA 断裂和复制突变,导致细胞凋亡。 | |||
T4327 |
Prexasertib dihydrochloride
LY2606368 (dihydrochloride),Prexasertib HCl,LY2606368 |
Apoptosis; Chk; S6 Kinase | Apoptosis; Cell Cycle/Checkpoint; MAPK; PI3K/Akt/mTOR signaling |
Prexasertib dihydrochloride (LY2606368) 是一种选择性的,ATP 竞争性的细胞周期检测点激酶 1 抑制剂,Ki 为 0.9 nM,IC50为 <1 nM。它抑制 CHK2(IC50=8 nM) 和 RSK1 (IC50=9 nM)。它引起双链 DNA 断裂和复制突变,导致细胞凋亡,有抗肿瘤活性。 | |||
T4310L2 |
Prexasertib mesylate
LY-2606368,LY2606368,LY 2606368 |
||
Prexasertib is a potent and selective Chk1/Chk2 inhibitor. Prexasertib increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. LY2606368 causes replication catastrophe and antitumor effects through CHK1-d | |||
T4310L |
Prexasertib lactate hydrate
Prexasertib monolactate monohydrate,LY-2606368,LY 2606368,LY2606368,Prexasertib monolactate monohydrate salt |
||
Prexasertib is an effective and selective Chk1/Chk2 inhibitor. Prexasertib causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. |